The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib
Abstract Recently Food and Drug Administration (FDA)-approved pralsetinib (BLU-667) and selpercatinib (LOXO-292) are RET-selective protein tyrosine kinase inhibitors for treating RET-altered cancers, but whether they have distinct activity was unknown. The L730V/I mutations at the roof of the solven...
Guardado en:
Autores principales: | Tao Shen, Xueqing Hu, Xuan Liu, Vivek Subbiah, Blaine H. M. Mooers, Jie Wu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a56a59cbb9894e42849b0e49e6d4e170 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Acta Nº730
por: Banco Central de Chile
Publicado: (2019) -
P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO)
por: Yaogeng Wang, et al.
Publicado: (2021) -
A secondary RET mutation in the activation loop conferring resistance to vandetanib
por: Takashi Nakaoku, et al.
Publicado: (2018) -
Resolution 730(XXXVII). Committee on South-South Cooperation
Publicado: (2018) -
Resolución 730(XXXVII). Comité de Cooperación Sur-Sur
Publicado: (2018)